What was the market valuation of the China car t-cell-therapy market in 2024?

The market valuation was $692.85 Million in 2024. Read More

What is the projected market valuation for the China car t-cell-therapy market by 2035?

The projected market valuation for 2035 is $3374.7 Million. Read More

What is the expected CAGR for the China car t-cell-therapy market during the forecast period 2025 - 2035?

The expected CAGR during the forecast period 2025 - 2035 is 15.48%. Read More

Which therapeutic area had the highest valuation in the China car t-cell-therapy market?

Oncology had the highest valuation, ranging from $300.0 Million to $1500.0 Million. Read More

What are the key cell source segments in the China car t-cell-therapy market?

The key cell source segments include Autologous, Allogeneic, and Gene-Edited, with valuations from $142.85 Million to $1500.0 Million. Read More

Which indication segment is projected to show significant growth in the China car t-cell-therapy market?

Non-Hodgkin Lymphoma is projected to show significant growth, with valuations from $300.0 Million to $1500.0 Million. Read More

What is the market valuation range for infectious diseases in the China car t-cell-therapy market?

The market valuation range for infectious diseases is from $242.85 Million to $1124.7 Million. Read More

Who are the leading companies in the China car t-cell-therapy market?

Leading companies include Gilead Sciences, Novartis, and Bristol-Myers Squibb, among others. Read More

What is the expected market performance for hospitals as end users in the China car t-cell-therapy market?

Hospitals are expected to have a valuation range from $276.42 Million to $1350.0 Million. Read More

How do research institutes contribute to the China car t-cell-therapy market?

Research institutes contribute with a valuation range from $138.21 Million to $675.0 Million. Read More

China Car T Cell Therapy Market

ID: MRFR/Pharma/48116-HCR

200 Pages

Rahul Gotadki

Last Updated: April 06, 2026

China CAR T Cell Therapy Market Research Report By Therapeutic Area (Oncology, Autoimmune Diseases, Infectious Diseases), By Cell Source (Autologous, Allogeneic, Gene-Edited), By Indication (Acute Lymphoblastic Leukemia, Non-Hodgkin Lymphoma, Multiple Myeloma), andBy End-user (Hospitals, Research Institutes, Cancer Treatment Centers) - Growth & Industry Forecast 2025 To 2035

China Car T Cell Therapy Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)15.48%

2024 Market Size$ 692.85 Million

2025 Market Size$ 800.1 Million

2035 Market Size$ 3,374.7 Million

Key Players

Gilead Sciences

Novartis

Bristol-Myers Squibb

Celgene

Amgen

Merck & Co.

Trends

Regulatory Advancements
Rising Incidence of Malignancies
Collaborative Research Initiatives

Opportunities

Supportive Regulatory Environment
Growing Patient Awareness and Demand
Increasing Investment in Biotechnology

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Chemicals and Materials, BY Therapeutic Area (USD Million)
  1. 4.1.1 Oncology
  2. 4.1.2 Autoimmune Diseases
  3. 4.1.3 Infectious Diseases
2. 4.2 Chemicals and Materials, BY Cell Source (USD Million)
  1. 4.2.1 Autologous
  2. 4.2.2 Allogeneic
  3. 4.2.3 Gene-Edited
3. 4.3 Chemicals and Materials, BY Indication (USD Million)
  1. 4.3.1 Acute Lymphoblastic Leukemia
  2. 4.3.2 Non-Hodgkin Lymphoma
  3. 4.3.3 Multiple Myeloma
4. 4.4 Chemicals and Materials, BY End User (USD Million)
  1. 4.4.1 Hospitals
  2. 4.4.2 Research Institutes
  3. 4.4.3 Cancer Treatment Centers
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Chemicals and Materials
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Chemicals and Materials
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Gilead Sciences (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Novartis (CH)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Bristol-Myers Squibb (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Celgene (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Amgen (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Merck & Co. (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 AstraZeneca (GB)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Janssen Pharmaceuticals (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Bluebird Bio (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 CHINA MARKET ANALYSIS BY THERAPEUTIC AREA
3. 6.3 CHINA MARKET ANALYSIS BY CELL SOURCE
4. 6.4 CHINA MARKET ANALYSIS BY INDICATION
5. 6.5 CHINA MARKET ANALYSIS BY END USER
6. 6.6 KEY BUYING CRITERIA OF CHEMICALS AND MATERIALS
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF CHEMICALS AND MATERIALS
9. 6.9 DRIVERS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
10. 6.10 RESTRAINTS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
11. 6.11 SUPPLY / VALUE CHAIN: CHEMICALS AND MATERIALS
12. 6.12 CHEMICALS AND MATERIALS, BY THERAPEUTIC AREA, 2024 (% SHARE)
13. 6.13 CHEMICALS AND MATERIALS, BY THERAPEUTIC AREA, 2024 TO 2035 (USD Million)
14. 6.14 CHEMICALS AND MATERIALS, BY CELL SOURCE, 2024 (% SHARE)
15. 6.15 CHEMICALS AND MATERIALS, BY CELL SOURCE, 2024 TO 2035 (USD Million)
16. 6.16 CHEMICALS AND MATERIALS, BY INDICATION, 2024 (% SHARE)
17. 6.17 CHEMICALS AND MATERIALS, BY INDICATION, 2024 TO 2035 (USD Million)
18. 6.18 CHEMICALS AND MATERIALS, BY END USER, 2024 (% SHARE)
19. 6.19 CHEMICALS AND MATERIALS, BY END USER, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY THERAPEUTIC AREA, 2025-2035 (USD Million)
  2. 7.2.2 BY CELL SOURCE, 2025-2035 (USD Million)
  3. 7.2.3 BY INDICATION, 2025-2035 (USD Million)
  4. 7.2.4 BY END USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

China Car T Cell Therapy Market Segmentation

China Car T Cell Therapy Market By Therapeutic Area (USD Million, 2025-2035)

Oncology
Autoimmune Diseases
Infectious Diseases

China Car T Cell Therapy Market By Cell Source (USD Million, 2025-2035)

Autologous
Allogeneic
Gene-Edited

China Car T Cell Therapy Market By Indication (USD Million, 2025-2035)

Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma

China Car T Cell Therapy Market By End User (USD Million, 2025-2035)

Hospitals
Research Institutes
Cancer Treatment Centers

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”